Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.

ABSTRACT: Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in the United States over the last 4 years, AML remains a major area of unmet medical need among hematologic malignancies. In this review, we discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations. In addition, we review progress in immune targeting of AML through anti-CD47, anti-SIRPα, and anti-TIM-3 antibodies; bispecific and trispecific antibodies; and new cellular therapies in development for AML.

SUBMITTER: Bewersdorf JP 

PROVIDER: S-EPMC8973851 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature